tiprankstipranks
Trending News
More News >
PaySign Inc Class B (PAYS)
:PAYS
US Market

PaySign (PAYS) AI Stock Analysis

Compare
1,068 Followers

Top Page

PAYS

PaySign

(NASDAQ:PAYS)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
$5.50
▲(0.92% Upside)
PaySign's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company's robust revenue growth and operational improvements are noteworthy. However, the high P/E ratio and technical indicators suggest caution, as the stock may be overvalued and lacks strong momentum. The settlement of legal actions is a positive corporate event, enhancing governance and reducing litigation risks.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market expansion and product adoption, positioning PaySign for continued success in its industry.
Operational Efficiency
Improved operational efficiency enhances profitability and supports sustainable growth, allowing PaySign to better manage costs and resources.
Cash Generation
Strong cash generation provides financial flexibility for investments and debt servicing, contributing to long-term stability and growth potential.
Negative Factors
Net Profit Margin Decline
A declining net profit margin indicates pressure on profitability, which could impact PaySign's ability to reinvest in growth and maintain competitive positioning.
Increased Operating Expenses
Rising operating expenses can strain margins and reduce profitability, potentially limiting PaySign's ability to invest in strategic initiatives.
Regulatory Delays
Regulatory delays hinder new product launches, impacting revenue diversification and growth opportunities in the long term for PaySign.

PaySign (PAYS) vs. SPDR S&P 500 ETF (SPY)

PaySign Business Overview & Revenue Model

Company DescriptionPaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. The company also develops prepaid card programs for corporate incentive and rewards, including consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, it offers and Per Diem/Corporate Expense Payments that allows businesses, and non–profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, the company provides payment claims processing and other administrative services; pharmacy-based voucher and copay, and medical claims and debit-based affordability programs; PaySign Premier, a demand deposit account debit card; and payment solution for source plasma collection centers, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is based in Henderson, Nevada.
How the Company Makes MoneyPaySign generates revenue through multiple streams, primarily by charging fees for its prepaid card programs and transaction processing services. The company's revenue model includes card issuance fees, transaction fees for point-of-sale purchases, and monthly service fees for ongoing account management. Additionally, PaySign benefits from interchange fees received from card transactions. The company has established strategic partnerships with various organizations, including healthcare providers and payment processors, which contribute to its earnings by expanding its customer base and enhancing its service offerings. These partnerships enable PaySign to deliver tailored solutions that meet the specific needs of its clients, thereby driving additional revenue growth.

PaySign Earnings Call Summary

Earnings Call Date:Nov 12, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 24, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue and income growth, expansion in patient affordability programs, and operational efficiencies. However, challenges include plasma industry oversupply, regulatory delays, and increased operating expenses.
Q3-2025 Updates
Positive Updates
Record Revenue Growth
PaySign reported record revenue of $21.6 million, a 41.6% increase year-over-year.
Strong Adjusted EBITDA Growth
Adjusted EBITDA reached a record $5 million, up 78% from the previous year.
Significant Net Income Increase
Net income rose by 54% to $2.2 million, or $0.04 per fully diluted share.
Patient Affordability Business Expansion
The patient affordability business generated $7.9 million in revenue, a 142% increase from the prior year's quarter.
Operational Efficiencies Achieved
Meaningful operational efficiencies were achieved during the quarter.
Expansion of Patient Support Center
Opened a new 30,000 square foot patient support center, quadrupling support capacity.
Improved Gross Profit Margins
Gross profit margin improved by 72 basis points to 56.3%.
Increased Program Count
Ended the quarter with 105 active programs, expecting to reach 125 to 135 by year-end.
Negative Updates
Plasma Industry Challenges
The plasma industry continues to face an oversupply of sourced plasma, which is expected to normalize in 2026.
Revenue Per Plasma Center Decline
Revenue per plasma center declined to $7,122 due to new centers not reaching full maturity and existing centers impacted by plasma oversupply.
Increased Operating Expenses
Compensation and benefits increased by 20.3%, and stock compensation increased by 32%.
Regulatory Delays for BECCS
Awaiting FDA 510 clearance for the BECCS, causing delays in launching this business line.
Company Guidance
During the PaySign, Inc. Third Quarter 2025 Earnings Conference Call, the company reported record financial and operational achievements. Revenue for the quarter reached $21.6 million, marking a 41.6% increase year-over-year, while adjusted EBITDA rose by 78% to $5 million. Net income grew by 54% to $2.2 million, translating to $0.04 per fully diluted share. The patient affordability business significantly contributed to this growth, with revenue soaring 142% to $7.9 million. The company ended the quarter with 105 active programs and anticipates increasing this number to between 125 and 135 by year-end. In the plasma donor compensation segment, revenue increased by 12.4% to $12.9 million despite a reduction of 12 centers, totaling 595 active centers. PaySign also highlighted operational advancements, including the opening of a new 30,000-square-foot patient support center, which quadruples its support capacity. Looking ahead, the company raised its 2025 revenue guidance to between $80.5 million and $81.5 million, with an anticipated adjusted EBITDA range of $19 million to $20 million.

PaySign Financial Statement Overview

Summary
PaySign demonstrates strong revenue growth and improving operational efficiency. Despite some pressure on net profitability, the company maintains a healthy balance sheet with low leverage and strong cash flows, positioning it well for future growth and stability. However, the relatively low net profit margin and stockholders' equity warrant careful monitoring to ensure long-term financial health.
Income Statement
75
Positive
PaySign showed a strong revenue growth of 23.5% over the past year, indicating a positive trajectory. The gross profit margin stands at 55.1%, which is solid for the industry. However, the net profit margin has decreased to 6.5% from 13.7% last year, indicating some profitability pressure. The EBIT margin has improved to 1.7%, recovering from negative figures in prior years, showing signs of operational improvement.
Balance Sheet
70
Positive
The debt-to-equity ratio is low at 0.1, indicating minimal leverage, which is beneficial for financial stability. Return on equity is 12.5%, showing reasonable profitability relative to shareholder equity. The equity ratio is 17%, which is moderate and suggests a balanced capital structure. However, the stockholders' equity is relatively low compared to total liabilities, indicating potential risk if liabilities increase.
Cash Flow
80
Positive
Operating cash flow increased to $22.9 million, showcasing robust cash generation capabilities. Free cash flow also showed growth, which is a positive sign for future investments and debt servicing. The operating cash flow to net income ratio is high at 6.0, indicating strong cash conversion efficiency. The free cash flow to net income ratio is 5.9, reinforcing the company's strong cash position relative to earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue74.88M58.38M47.27M38.03M29.46M24.12M
Gross Profit44.80M32.20M24.14M20.95M14.71M9.30M
EBITDA14.38M7.02M3.86M2.79M-1.12M-5.79M
Net Income7.56M3.82M6.46M1.03M-2.72M-9.14M
Balance Sheet
Total Assets209.51M179.03M146.60M108.24M84.05M67.83M
Cash, Cash Equivalents and Short-Term Investments7.53M10.77M16.99M9.71M7.39M7.83M
Total Debt6.08M2.93M3.31M3.67M4.01M4.33M
Total Liabilities163.75M148.59M122.11M91.95M71.06M54.60M
Stockholders Equity45.76M30.44M24.49M16.29M12.99M13.24M
Cash Flow
Free Cash Flow9.84M13.46M20.57M21.23M12.55M10.43M
Operating Cash Flow18.67M22.95M27.62M25.32M15.23M13.78M
Investing Cash Flow-10.84M-9.49M-7.05M-4.09M-2.68M-3.34M
Financing Cash Flow150.32K-466.25K-1.12M0.00192.14K-72.86K

PaySign Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.45
Price Trends
50DMA
5.34
Positive
100DMA
5.56
Negative
200DMA
4.87
Positive
Market Momentum
MACD
0.03
Negative
RSI
52.53
Neutral
STOCH
65.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAYS, the sentiment is Positive. The current price of 5.45 is above the 20-day moving average (MA) of 5.25, above the 50-day MA of 5.34, and above the 200-day MA of 4.87, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 52.53 is Neutral, neither overbought nor oversold. The STOCH value of 65.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAYS.

PaySign Risk Analysis

PaySign disclosed 28 risk factors in its most recent earnings report. PaySign reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Global and regional economic conditions could harm our business. Q4, 2023

PaySign Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$299.98M40.9120.36%32.61%-8.26%
69
Neutral
$2.10B31.109.79%10.58%-45.52%
68
Neutral
$457.07M12.0526.84%-6.57%-29.62%
65
Neutral
$2.96B-1,505.490.58%24.71%99.52%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
51
Neutral
$602.04M-2.80-17.60%-0.58%-57.43%
48
Neutral
$348.03M-1.97-48.63%101.97%58.61%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PAYS
PaySign
5.38
2.45
83.62%
IMXI
International Money Express
15.38
-5.65
-26.87%
RPAY
Repay Holdings
3.83
-4.01
-51.15%
AVPT
AvePoint
13.70
-4.06
-22.86%
PAYO
Payoneer
5.90
-4.03
-40.58%
BKKT
Bakkt Holdings, Inc. Class A
10.01
-16.54
-62.30%

PaySign Corporate Events

Legal Proceedings
PaySign Settles Stockholder Derivative Actions
Positive
Sep 16, 2025

On November 25, 2024, Paysign, a company involved in financial services, entered into a Stipulation and Agreement of Settlement to resolve stockholder derivative actions pending in the United States District Court for the District of Nevada. These actions alleged violations of the Exchange Act, breaches of fiduciary duty, unjust enrichment, and waste. The settlement, which is not an admission of fault, requires Paysign to adopt corporate governance reforms and will result in the dismissal of the actions with prejudice, pending court approval. The settlement is seen as beneficial for the company and its shareholders, avoiding the costs and risks of litigation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025